1,469,743 Tests captured across one company's entire precision medicine portfolio in 15 months.
Enterprise diagnostic data partnership
When Your Portfolio Grows Faster Than Your Data Infrastructure, Something Has to Give
The diagnostic data partnership that grew as fast as the portfolio did.
One of oncology's most recognised portfolios. Eleven biomarkers. Six tumour types. Some of the highest-earning biomarker-driven therapies in the world - including a BRCA-targeted PARP inhibitor approved across ovarian, breast, prostate and pancreatic cancers generating billions in annual revenue.
A precision medicine strategy that leads the industry. And a data infrastructure that couldn't keep pace with it.
Fragmented data sources
Multiple vendors, inconsistent data, no single view across the portfolio. Commercial and medical teams working from different intelligence on the same patients.
No real-time visibility
Field teams operating on monthly data cycles - systematically late to physicians who already had eligible patients and had already made treatment decisions.
Infrastructure that couldn't scale
Every new therapy area, every new biomarker, every new indication required a new contracting conversation. The portfolio was outpacing the data model built to support it.
One Partner. One System. Every Biomarker.
Diaceutics became the enterprise diagnostic data backbone - a single contracting relationship replacing multiple vendors, delivering consistent intelligence across the full portfolio through DXRX.
"When we want to access a new dataset, it's largely plug-and-play rather than starting from scratch as with other providers."
Precision Medicine Lead
Client Company
Precision Medicine Engagement
In-field lab and account engagement going directly into hospitals, reference centres and community labs - understanding the barriers to testing that data alone cannot surface and acting on them. Including pre-launch infrastructure building for therapies not yet approved.Physician Engage
Six active Physician Engage projects linked directly to internal Signal triggered email campaigns reaching physicians within 24 hours of a confirmed positive result - not before and not after. Open rates consistently above industry benchmarks across every active workstream.The enterprise foundation
Four connected data products delivered weekly, monthly and quarterly depending on preference through DXRX - Signal for real-time patient identification - alerting physicians to eligible patients in as little as 24 hours of a confirmed diagnostic result - alongside Physician Mapping, Lab Mapping and Testing Rate Tracking to give a complete, continuously updated view of the diagnostic landscape across every indication.What Happens When a Diagnostic Data Partnership Works
2022
Pre-enterprise project work begins. Data proposal accepted.
June 2023
Enterprise partnership signed. Single contract replacing multiple vendors across lung, breast, ovarian and (in July 2023) HER2 tumour agnostic workstreams.
2024
Imfinzi added. Portfolio continues to expand. Disease coverage improvements documented across NSCLC, breast and ovarian.
2025
Six active Physician Engage projects running. PME programmes live across two indications. Biopharma unit expansion begins.
2026
Pre-launch testing infrastructure being built for a therapy not yet approved - mapping labs, engaging accounts and identifying gaps before the regulatory decision lands, not after. Every expansion happened because the previous chapter delivered.
The numbers that matter
1,469,743
tests captured across the portfolio in 15 months - every test tracked, every biomarker covered, one partner.
25
%
Average open rate across Physician Engage campaigns - against an IQVIA industry average of 15.5%. On the lead brand nurture campaign specifically, 31% versus 15.5%. Physicians opening because a relevant patient had just appeared in their caseload.
8
%
click rate on the same campaigns - physicians not just opening, but acting.
304,805
patients with positive genetic or diagnostic test results identified in the same period - across six tumour types simultaneously.
26,009
unique physicians alerted - the right physician, at the right moment, across eleven active biomarker workstreams.
+
9
%
disease coverage in NSCLC, +5% in breast cancer, +5% in ovarian cancer - directly attributable to enhanced multi-modal data from the enterprise partnership.
"Instead of sales teams calling on providers every few weeks without knowing whether they have an eligible patient, Diaceutics' signal data allows engagement to happen when a physician actively has a patient they are thinking about. That precision is better for physicians, better for patients, and more effective commercially."
Precision Medicine Lead
Client Company
Your Portfolio Shouldn’t Outgrow Your Data
Portfolios don't wait for data infrastructure to catch up. Neither do we.
A growing portfolio needs a partner that grows with it. Not a new contract every time. One relationship.
Built to scale. One Partner. Every Biomarker. Every Stage.
Learn More
Signal - Real-time patient identification
How Diaceutics identifies biomarker-positive patients within 24 hours of a confirmed diagnostic result.
Relay - The commercialization model for diagnostic-driven therapies
How Diaceutics coordinates testing, intelligence and engagement into one connected system.
DXRX - The diagnostic intelligence platform
How Diaceutics delivers real-time diagnostic data, physician mapping and testing rate tracking across an entire precision medicine portfolio.
Share:
